Cel-Sci Corp. (CVM)
XASE:CVM
Want to see CVM full AI Analyst Report?
CVM Stock Chart & Stats
$5.19
-$0.03(-7.92%)
At close: 4:00 PM EST
$5.19
-$0.03(-7.92%)
Day’s Range― - ―
52-Week Range$0.89 - $13.48
Previous Close$0.36
Volume1.47M
Average Volume (3M)125.69K
Market Cap
$12.06M
Enterprise Value$16.38M
Total Cash (Recent Filing)$1.89M
Total Debt (Recent Filing)$8.51M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.47
Shares Outstanding8,493,111
10 Day Avg. Volume66,836
30 Day Avg. Volume125,686
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap1.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.55
Enterprise Value/Ebitda-0.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
GMP Manufacturing And CDMO ServicesCEL-SCI's in-house GMP manufacturing and CDMO capability is a durable operational asset. It can generate recurring project revenue, deepen technical expertise, and enable partnering or toll-manufacture deals that diversify cash flow away from a single drug outcome, improving long-term optionality.
Middle East Commercialization PartnershipThe Amarox distribution and revenue-sharing deal creates a structural commercialization pathway in Saudi Arabia (and potentially the GCC). This expands geographic market access, allocates regulatory/marketing responsibility externally, and establishes a non-US route to revenue if regulatory milestones succeed.
Relatively Moderate Historical LeverageCompared with many clinical-stage peers, CEL-SCI's historical debt metrics are moderate, implying lower fixed financing costs and more flexibility to fund operations or absorb project delays. Moderate leverage supports capacity to pursue partnerships or manufacturing contracts without extreme interest pressure.
Bears Say
Pre-commercial Status / No Product RevenueAbsence of product sales means long-term viability depends on clinical and regulatory success for Multikine or scaling CDMO contracts. Without an approved product, revenue is episodic and uncertain, leaving durable growth contingent on binary trial/regulatory outcomes and successful commercialization execution.
Persistent Negative Cash Flow And Operating BurnConsistent multi-year operating cash deficits create structural runway pressure. Sustained -$18M to -$23M annual burn requires recurring financing or material service revenue growth; this constraint limits R&D scaling, strategic flexibility, and increases dilution risk until a stable revenue base is established.
Reliance On External FinancingDependence on equity/debt raises to fund operations is a durable vulnerability: market access, timing, and issuance terms dictate funding cost and dilution. If capital markets tighten or clinical/regulatory progress stalls, the company may face constrained options and increased shareholder dilution over time.
Cel-Sci News
CVM FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $0.89 and its highest was $13.48 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is $12.06M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is Aug 17, 2026 which is in 83 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on May 18, 2026. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.67.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 8,493,111 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -$0.67 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 20.28%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in CVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cel-Sci Corp.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Technical Analysis
Ownership Overview
7.25% Insiders
3.69% Mutual Funds
0.09% Other Institutional Investors
86.20% Public Companies and
Individual Investors